Jacques Simard,
#133,204
Most Influential Person Now
Jacques Simard,'s AcademicInfluence.com Rankings
Jacques Simard,philosophy Degrees
Philosophy
#6596
World Rank
#9654
Historical Rank
Logic
#3740
World Rank
#4940
Historical Rank

Download Badge
Philosophy
Why Is Jacques Simard, Influential?
(Suggest an Edit or Addition)Jacques Simard,'s Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (2017) (1644)
- Large-scale genotyping identifies 41 new loci associated with breast cancer risk (2013) (1063)
- Association analysis identifies 65 new breast cancer risk loci (2017) (922)
- The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds (1996) (866)
- A candidate prostate cancer susceptibility gene at chromosome 17p (2001) (568)
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
- MicroRNA Related Polymorphisms and Breast Cancer Risk (2014) (557)
- Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. (2003) (534)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
- Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants (2015) (471)
- Is dehydroepiandrosterone a hormone? (2005) (454)
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
- Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family (2005) (442)
- A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. (1995) (433)
- Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
- The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology (1997) (411)
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
- Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
- RAD51B in Familial Breast Cancer (2016) (366)
- BRCA2 germline mutations in male breast cancer cases and breast cancer families (1996) (363)
- A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
- DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role during Aging (1998) (350)
- DHEA and Its Transformation into Androgens and Estrogens in Peripheral Target Tissues: Intracrinology (2001) (348)
- Structure and Expression of a New Complementary DNA Encoding the almost Exclusive 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4-lsomerase in Human Adrenals and Gonads (1991) (345)
- Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families (1994) (325)
- BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (325)
- Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. (2020) (322)
- Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair (2015) (308)
- 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. (1999) (304)
- Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. (2000) (295)
- Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. (1989) (282)
- RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (2007) (276)
- DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology (1995) (270)
- The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers (2016) (267)
- Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues (1986) (249)
- Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
- Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
- The emergence of an ethical duty to disclose genetic research results: international perspectives (2006) (235)
- Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
- Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. (2005) (217)
- Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
- Congenital adrenal hyperplasia due to point mutations in the type II 3β–hydroxysteroid dehydrogenase gene (1992) (209)
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
- Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent (2016) (205)
- Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. (2006) (199)
- Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. (2010) (196)
- Structure of human type II 5 alpha-reductase gene. (1992) (192)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues. (1991) (174)
- Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes (1990) (173)
- Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. (1990) (171)
- EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium (1999) (166)
- Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. (2013) (163)
- A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. (2005) (161)
- Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. (2005) (154)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (149)
- Role of 17β-Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues (2000) (147)
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation (2018) (147)
- Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
- Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study (2009) (143)
- Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores (2017) (142)
- (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. (1997) (139)
- Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues (1992) (139)
- Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. (1996) (137)
- p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6 (1999) (135)
- The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. (1997) (134)
- Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. (1998) (128)
- Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
- Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
- Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk (2013) (120)
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (117)
- BRCA1 mutations in Ashkenazi Jewish women. (1995) (114)
- Prostate cancer susceptibility genes: lessons learned and challenges posed. (2003) (112)
- DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
- Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
- Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. (1990) (111)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
- Science behind total androgen blockade: from gene to combination therapy. (1993) (109)
- Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. (1989) (109)
- Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
- New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. (1999) (108)
- Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. (2015) (107)
- MOLECULAR BASIS OF CONGENITAL ADRENAL HYPERPLASIA DUE TO 3β-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY (1993) (105)
- Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats. (1989) (104)
- Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. (1986) (102)
- Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
- Structure and tissue-specific expression of 3ß-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues (1992) (97)
- The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. (2000) (96)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
- Genetic discrimination and life insurance: a systematic review of the evidence (2013) (94)
- Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy (1993) (93)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
- Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. (1991) (90)
- Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. (1998) (90)
- Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. (2015) (86)
- BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families (2005) (86)
- Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase. (1990) (84)
- GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. (2005) (82)
- Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
- Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin. (1993) (82)
- Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
- 11 Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues (1994) (80)
- Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
- The Tumor Suppressor PALB2: Inside Out. (2019) (77)
- Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro (1997) (77)
- Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. (1997) (76)
- Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model (2016) (76)
- Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. (1994) (76)
- BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
- Perspective: prostate cancer susceptibility genes. (2002) (75)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Induction of 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13 (1999) (73)
- Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3β‐hydroxy‐5‐ene steroid dehydrogenase/Δ5‐Δ4 isomerase (1989) (73)
- Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. (1991) (70)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency (1995) (70)
- Localization of 3β-Hydroxysteroid Dehydrogenase in Rat Brain as Studied by in Situ Hybridization (1994) (69)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. (1991) (67)
- Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. (1992) (65)
- Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. (1993) (65)
- The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. (1995) (64)
- Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. (1991) (64)
- Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation (2016) (63)
- Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. (1996) (62)
- Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. (1989) (62)
- Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium (2014) (62)
- Molecular biology and genetics of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family (1996) (61)
- Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
- Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
- Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. (1989) (60)
- No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency. (1994) (60)
- Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. (2015) (59)
- European polygenic risk score for prediction of breast cancer shows similar performance in Asian women (2020) (59)
- Characterization of macaque 3β-hydroxy-5-ene steroid dehydrogenase/Δ5-Δ4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate (1991) (59)
- Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. (1993) (59)
- Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. (2002) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
- Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells (1996) (58)
- Localization of 3β-Hydroxysteroid DehydrogenaseΔ5-Δ4-Isomerase in Rat Gonads and Adrenal Glands by Immunocytochemistry and in Situ Hybridization (1990) (56)
- Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. (2007) (56)
- Structure-function relationships of 3β-hydroxysteroid dehydrogenase: Contribution made by the molecular genetics of 3β-hydroxysteroid dehydrogenase deficiency (1997) (56)
- Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. (1993) (56)
- Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families (2005) (55)
- Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
- Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2019) (55)
- No Evidence of False Reassurance among Women with an Inconclusive BRCA1/2 Genetic Test Result (2005) (54)
- Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells. (1991) (54)
- Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2010) (53)
- Response of Symbiotic Endomycorrhizal Fungi to Estrogens and Antiestrogens (1997) (53)
- Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. (2007) (53)
- No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. (2006) (53)
- Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency. (1994) (53)
- Ontogeny and subcellular localization of 3β-hydroxysteroid dehydrogenase (3β-HSD) in the human and rat adrenal, ovary and testis (1992) (53)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
- Regulation of 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Expression and Activity in the Hypophysectomized Rat Ovary: Interactions between the Stimulatory Effect of Human Chorionic Gonadotropin and the Luteolytic Effect of Prolactin* (1990) (53)
- Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary (1986) (53)
- Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency. (1994) (52)
- Induction of 3β-Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines1. (1999) (52)
- Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. (2015) (51)
- Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat. (1992) (51)
- Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
- History of LHRH agonist and combination therapy in prostate cancer (1996) (50)
- Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families (2006) (50)
- Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast (2014) (49)
- Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. (1996) (48)
- Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity. (1992) (48)
- Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. (1990) (47)
- Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
- Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry (2016) (47)
- The emergence of an ethical duty to disclose genetic research results: international perspectives (2006) (47)
- Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis. (1990) (46)
- Genetic predisposition to ductal carcinoma in situ of the breast (2016) (46)
- Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families (2008) (45)
- A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
- EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium (2001) (45)
- Results of a genome‐wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium (2003) (45)
- Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. (1995) (44)
- Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (44)
- The 3β-Hydroxysteroid Dehydrogenase/Isomerase Gene Family: Lessons from Type II 3β-HSD Congenital Deficiency (1996) (44)
- A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. (2000) (43)
- Full oestrogenic activity of C19-Δ 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs (1988) (43)
- Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2 (2019) (43)
- Androgens and breast cancer. (1992) (43)
- Crucial role of cytokines in sex steroid formation in normal and tumoral tissues (2001) (42)
- Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization. (1988) (42)
- Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. (2011) (42)
- COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (41)
- Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. (1996) (41)
- Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. (1992) (41)
- New concepts on the androgen sensitivity of prostate cancer. (1987) (41)
- Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles? (2004) (41)
- Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells (1994) (41)
- Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2020) (40)
- A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. (2014) (40)
- Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36 (2000) (40)
- Interleukin‐6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin‐1α on apolipoprotein D and GCDFP‐15 expression in human breast cancer cells (1995) (39)
- Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract (1995) (39)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
- Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. (2015) (39)
- Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. (1993) (38)
- Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus (1991) (38)
- Personalized medicine and access to health care: potential for inequitable access? (2012) (38)
- Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer (2016) (38)
- Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. (1996) (38)
- Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary. (1989) (38)
- Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I) (2021) (38)
- Health Behaviors and Psychological Distress in Women Initiating BRCA1/2 Genetic Testing: Comparison with Control Population (2008) (37)
- Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
- AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study (2007) (37)
- Life insurance: genomic stratification and risk classification (2013) (37)
- Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. (2002) (37)
- Potent stimulatory effect of interleukin‐1α on apolipoprotein D and gross cystic disease fluid protein‐15 expression in human breast‐cancer cells (1994) (36)
- Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. (1994) (36)
- A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor (2019) (36)
- Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. (1986) (36)
- Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland. (1989) (36)
- An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. (2016) (35)
- Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (35)
- Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene. (1995) (35)
- Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus (1990) (34)
- Rapid modulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ 5-Δ 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat (1994) (33)
- Identification of three mutations in the low‐density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians (1998) (33)
- Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions (2014) (33)
- Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia (2017) (33)
- Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) (33)
- Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate (1990) (33)
- Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. (2019) (33)
- Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. (1994) (33)
- Family Communication Following BRCA1/2 Genetic Testing: A Close Look at the Process (2013) (32)
- Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs (1985) (32)
- Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. (1997) (32)
- Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. (2010) (32)
- Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase close to D1S514 and the centromeric D1Z5 locus (1995) (32)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
- A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. (2019) (31)
- Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study (2012) (31)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
- Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort (2018) (31)
- A common ancestor for mammalian 3 beta-hydroxysteroid dehydrogenase and plant dihydroflavonol reductase. (1990) (31)
- Functional characterization of 84 PALB2 variants of uncertain significance (2019) (30)
- Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. (1995) (30)
- Synthesis and antiestrogenic activity of diaryl thioether derivatives. (1994) (30)
- Dinucleotide repeat polymorphisms in the HSD3B2 gene. (1994) (29)
- Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
- Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland. (1988) (29)
- Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, DES-GLy-NH210] LHRH ethylamide on α-subunit and LHβ messenger ribonucleic acid levels in rat anterior pituitary cells in culture (1988) (29)
- Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion (1986) (29)
- Expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) and 17B-hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue (1991) (29)
- Functional characterization of the novel L108W and P186L mutations detected in the type II 3β-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia (1994) (29)
- Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. (1989) (29)
- On the readiness of physicians for pharmacogenomics testing: an empirical assessment (2017) (29)
- Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) (2009) (28)
- The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2006) (28)
- Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. (1999) (28)
- Glucocorticoids enhance activation of the human type II 3β-hydroxysteroid dehydrogenase/Δ5–Δ4 isomerase gene (2002) (28)
- Rapid restriction fragment analysis for screening four point mutations of the Low‐density lipoprotein receptor gene in French Canadians (1995) (27)
- Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells (2003) (27)
- Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) (2016) (27)
- A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (27)
- Return of Research Results: General Principles and International Perspectives (2011) (27)
- Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent. (2019) (27)
- Ontogenesis of 3β-Hydroxysteroid DehydrogenaseΔ5-Δ4 Isomerase in the Rat Adrenal as Revealed by Immunocytochemistry and in Situ Hybridization (1991) (27)
- Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. (1995) (26)
- Relative potencies of Flutamide and Casodex: preclinical studies (1996) (26)
- Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M200479-JLR200 (2003) (26)
- Purification, Cloning, Complementary DNA Structure, and Predicted Amino Acid Sequence of Human Estradiol 17β‐Dehydrogenase (1990) (26)
- A New Insight Into the Molecular Basis of 3β-Hydroxysteroid Dehydrogenase Deficiency (2000) (26)
- Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study (2018) (26)
- Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. (1999) (25)
- Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (25)
- Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk (2015) (25)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
- Macrophage Scavenger Receptor 1 999C>T (R293X) Mutation and Risk of Prostate Cancer (2005) (25)
- The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (25)
- Structure-function relationships and molecular genetics of the 3β-hydroxysteroid dehydrogenase gene family (1995) (24)
- Interactions between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR‐75‐1 Human Breast Cancer Cells (1990) (24)
- High risk genes predisposing to prostate cancer development—do they exist? (2000) (24)
- Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones. (1992) (23)
- The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations (2018) (23)
- Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. (2020) (23)
- Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver. (1994) (23)
- Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. (2001) (22)
- Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17. (1989) (22)
- Multiple signal transduction pathways mediate interleukin-4-induced 3β-hydroxysteroid dehydrogenase/Δ5–Δ4 isomerase in normal and tumoral target tissues (2001) (22)
- A new alternative splice variant of BRCA1 containing an additional in-frame exon. (2005) (22)
- Health professionals’ perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease (2019) (22)
- A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
- Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22. (1996) (22)
- FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium (2014) (22)
- Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges (2005) (22)
- Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(α)antracene (DMBA)-induced mammary tumors in the rat (1991) (22)
- Linkage analysis of 26 Canadian breast and breast-ovarian cancer families (1995) (21)
- Androgenic 17β-hydroxysteroid dehydrogenase activity of expressed rat type I 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (1992) (21)
- Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3). (1991) (21)
- Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. (1987) (21)
- Multiple Signaling Pathways Mediate Interleukin-4-Induced 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells (2000) (21)
- Binding of a member of the NF1 family of transcription factors to two distinct cis-acting elements in the promoter and 5'-flanking region of the human cellular retinol binding protein 1 gene. (1994) (21)
- Stimulation of Androgen‐Dependent Gene Expression by the Adrenal Precursors Dehydroepiandrosterone and Androstenedione in the Rat Ventral Prostate (1990) (21)
- Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (20)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
- Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History (2020) (20)
- Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. (2018) (20)
- Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release (1987) (20)
- Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec (2011) (20)
- Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (20)
- Androgenic 17 beta-hydroxysteroid dehydrogenase activity of expressed rat type I 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase. (1992) (20)
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
- Mapping of the regulatory subunits RIβ and RIIβ of cAMP-Dependent protein kinase genes on human chromosome 7 (1992) (19)
- Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. (2021) (19)
- Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium (2017) (19)
- Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13. (1992) (19)
- Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. (1990) (19)
- BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. (2003) (18)
- ["Intracrinology". Autonomy and freedom of peripheral tissues]. (1995) (18)
- Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase. (1997) (18)
- Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. (1998) (18)
- Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study (2021) (18)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. (2005) (18)
- Medical Genetic Counseling for Breast Cancer in Primary Care: A Synthesis of Major Determinants of Physicians' Practices in Primary Care Settings (2014) (17)
- Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
- Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution (2005) (17)
- A focus group study on breast cancer risk presentation: one format does not fit all (2012) (17)
- Localization and regulation of expression of the FAR-17A gene in the hamster flank organs. (1996) (17)
- Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada (2021) (17)
- Use of Dietary Supplements Among Women at High Risk of Hereditary Breast and Ovarian Cancer (HBOC) Tested for Cancer Susceptibility (2006) (17)
- Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers (2017) (17)
- Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing (2013) (17)
- Multiple Factors Controlling ACTH Secretion at the Anterior Pituitary Level (1987) (17)
- Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium (2019) (17)
- Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. (1999) (16)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
- Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10. (1992) (16)
- Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells (1990) (16)
- Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
- The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. (1994) (16)
- Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. (2008) (15)
- SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival (2015) (15)
- Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
- A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
- CYP17 and breast cancer: no overall effect, but what about interactions? (2005) (15)
- Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. (2000) (15)
- Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) (14)
- Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. (2015) (14)
- Self-reported mammography use following BRCA1/2 genetic testing may be overestimated (2012) (14)
- Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. (2014) (14)
- No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study (2009) (13)
- Analysis of 17β-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer (2009) (13)
- Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk (2013) (13)
- The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes (2015) (13)
- Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency. (1997) (13)
- Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives (2019) (13)
- Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. (2004) (13)
- Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. (2002) (12)
- Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. (1992) (12)
- Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada) (2018) (12)
- A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (12)
- Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. (2001) (12)
- Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening (2018) (12)
- Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry (2019) (12)
- 17α-Hydroxylase/17,20-Lyase Deficiency Due to Novel Compound Heterozygote Mutations: Treatment for Tall Stature in a Female with Male Pseudohermaphroditism and Spontaneous Puberty in her Affected Sister (2005) (12)
- The association between weight at birth and breast cancer risk revisited using Mendelian randomisation (2018) (12)
- Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue. (1991) (12)
- PALB2 Variants: Protein Domains and Cancer Susceptibility. (2020) (11)
- Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers (2010) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. (1994) (11)
- Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer (2007) (11)
- Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. (1995) (11)
- Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study (2011) (11)
- Identification and characterization of novel associations in the CASP 8 / ALS 2 CR 12 region on chromosome 2 with breast cancer risk (2014) (11)
- Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (10)
- AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study (2007) (10)
- Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries (2019) (10)
- Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat. (1994) (10)
- The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
- Effectiveness of Risk-Reducing Salpingo-Oophorectomy in Preventing Ovarian Cancer in a High-Risk French Canadian Population (2012) (10)
- Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families (2017) (9)
- Variations of pre‐proNPY mRNA in the arcuate nucleus during the rat estrous cycle (1992) (9)
- Formation and degradation of dihydrotestosterone by recombinant members of the rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase family (1994) (9)
- Potent Antagonism between Estrogens and Androgens on GCDFP‐15 Expression and Cell Growth in the ZR‐75‐1 Human Breast Cancer Cells a (1990) (9)
- Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores (2021) (9)
- Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing (2007) (9)
- Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk (2020) (9)
- Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. (2004) (9)
- Opposite effects of prolactin and corticosterone on the expression and activity of 3β-hydroxysteroid dehydrogenase/δ5-δ4 isomerase in rat skin (1994) (9)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
- Localization of Peptide Gene Expression by in Situ Hybridization at Electron Microscopic Level (1989) (9)
- Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
- PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 (2017) (9)
- Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture (1986) (9)
- Estimated potency of casodex: A problematic design [1] (multiple letters) (1997) (8)
- Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"? (2017) (8)
- Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation (2015) (8)
- Functional analysis of promoter variants in KU70 and their role in cancer susceptibility (2012) (8)
- Variations of pre-prosomatostatin MRNA levels in the hypothalamic periventricular nucleus during the rat estrous cycle (1991) (8)
- Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues (1997) (8)
- Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (2022) (8)
- Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis. (1992) (7)
- Polygenic risk scores for prediction of breast cancer risk in Asian populations (2021) (7)
- Systematic mixed-methods reviews are not ready to be assessed with the available tools. (2011) (7)
- Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? (2016) (7)
- Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer (2008) (7)
- Open science precision medicine in Canada: Points to consider (2019) (7)
- Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility (2012) (7)
- Assignment of the gene encoding the catalytic subunit Cβ of CAMP-dependent protein kinase to the p36 band on chromosome (1992) (7)
- Estimated potency of Casodex: a problematic design. (1997) (7)
- Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate. (1991) (6)
- Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers (2021) (6)
- Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study (2022) (6)
- Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element (2021) (6)
- Common breast cancer risk loci predispose to distinct tumor subtypes (2019) (6)
- Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
- Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin. (1990) (6)
- Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (6)
- Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers (2012) (6)
- The AIB 1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers (2006) (6)
- Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (6)
- No Evidence of BRCA 1 / 2 Genomic Rearrangements in High-Risk French-Canadian Breast / Ovarian Cancer Families (2009) (5)
- ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry (2016) (5)
- Using the Impact of Event Scale to Evaluate Distress in the Context of Genetic Testing for Breast Cancer Susceptibility (2006) (5)
- CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (5)
- Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family Molecular Biology of the 3{beta}-Hydroxysteroid (2005) (5)
- Potential of polygenic risk scores for improving population estimates of women’s breast cancer genetic risks (2021) (5)
- Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer (2008) (5)
- Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase. (1989) (5)
- Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. (1990) (5)
- SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation (2015) (5)
- Type I Protein C Deficiency in French Canadians: Evidence of a Founder Effect and Association of Specific Protein C Gene Mutations with Plasma Protein C Levels (1998) (5)
- Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer (2020) (5)
- Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects (2021) (5)
- Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals (2021) (5)
- Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control (2019) (5)
- Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7. (1992) (5)
- Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer (2016) (5)
- Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization. (1991) (5)
- Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians (2003) (5)
- Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study (2014) (4)
- 3β-Hydroxysteroid Dehydrogenase Deficiency (2014) (4)
- Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers (2016) (4)
- Androgens, DHEA and breast cancer (2005) (4)
- Cloning of the human androgen receptor cDNA (1987) (4)
- Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening? (2021) (4)
- Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers (2005) (4)
- DSNetwork: An Integrative Approach to Visualize Predictions of Variants’ Deleteriousness (2019) (4)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- Molecular Cloning of Rat 3β-HSD: Structure of Two Types of cDNAs and Differential Expression of Corresponding mRNAs in the Ovary (1991) (4)
- Mendelian randomisation study of smoking exposure in relation to breast cancer risk (2021) (3)
- Erratum: Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer (Journal of Medical Genetics (2007) 44, (107-121)) (2007) (3)
- No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families. (2017) (3)
- Genomic organization and expression of the mouse Brca2 gene. (2002) (3)
- A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study (2021) (3)
- Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. (2020) (3)
- First World Congress: Hormonal and Genetic Basis of Sexual Differentiation Disorders (2002) (3)
- Characterization of the guinea pig 3β-hydroxysteroid dehydrogenase/Δ5–Δ4-isomerase expressed in the adrenal gland and gonads (2005) (3)
- Abstract 2598: Predicting breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers using polygenic risk scores (2016) (3)
- Stimulatory effect of adrenal steroids on LHRH-induced LH release in rat pituitary cells in culture (1984) (3)
- Pure Antagonistic Effect of a New Steroidal Antiestrogen in Rat Anterior Pituitary Cells in Culture and in Mouse Uterus (1990) (3)
- Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data (2021) (3)
- Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer (2020) (3)
- Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus. (1995) (3)
- Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin. (1994) (3)
- Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) (3)
- The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers (2011) (3)
- Third- and Fourth-Generation SERMs (2002) (3)
- rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk (2016) (2)
- Two truncating variants in FANCC and breast cancer risk (2019) (2)
- Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture. (1988) (2)
- EM-652 (SCH57068), a pure SERM in the mammary gland and endometrium (2001) (2)
- A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women (2022) (2)
- VEXOR: an integrative environment for prioritization of functional variants in fine‐mapping analysis (2017) (2)
- Males With 17β-Hydroxysteroid Dehydrogenase Deficiency (2003) (2)
- Women’s perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform (2022) (2)
- Genetic testing, physicians and the law: will the tortoise ever catch up with the hare? (2010) (2)
- Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase at the human HSDβ3 locus (1p11–p13) (1991) (2)
- Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. (1994) (2)
- Structure and Control of Expression of the 3βHSD and 17βHSD Genes in Classical Steroidogenic and Peripheral Intracrine Tissues (1993) (2)
- 26 Blockage of the potent estrogenic activity of 5-androstene-3 8, 17 β-diol (Δ5-diol) and dehydroepiandrosterone (DHEA) by the antiestrogen LY-156758 in rat anterior pituitary cells in culture (1985) (2)
- DHEA, The Precursor of Androgens and Estrogens in Peripheral Tissues in the Human: Intracrinology (2000) (2)
- Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. (2019) (2)
- Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study (2022) (2)
- BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1 (2003) (2)
- Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. (2022) (2)
- Molecular Genetics, Structure-Function Relationships, and Tissue-Specific Expression and Regulation of the 3βHSD Gene Family (1994) (2)
- Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads. (2005) (2)
- Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13). (1991) (2)
- Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience (2004) (2)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
- Structure-Function Relationships of Multiple Rat Members of the 3β-Hydroxysteroid Dehydrogenase Family (1993) (1)
- Survey of primary care physicians’ views about breast and ovarian cancer screening for true BRCA1/2 non-carriers (2019) (1)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
- Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (1)
- Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project (2015) (1)
- [From the gene to the clinic: prostate cancer death can now be an exception?]. (2003) (1)
- A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (1)
- Unoccupied androgen receptors are biologically active in pituitary gonadotrophs (1984) (1)
- VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis. (2017) (1)
- Induction of 3 b -Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines* (1999) (1)
- Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (1)
- Identifying 31 novel breast cancer susceptibility loci using data from genome-wide association studies conducted in Asian and European women (2019) (1)
- Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
- HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. (2005) (1)
- Erratum: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast Cancer Res (2020) 22 (8) DOI: 10.1186/s13058-020-1247-4) (2020) (1)
- Influence of the Duration of Androgen Deprivation on the Sensitivity of the Rat Ventral Prostate to Dehydroepiandrosterone and Androstenedione (1990) (1)
- Rare germline copy number variants (CNVs) and breast cancer risk (2022) (1)
- Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family. (1994) (1)
- Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (1)
- Lessons learned and challenges posed in cancer genetics (2013) (1)
- Genetic predisposition to ductal carcinoma in situ of the breast (2016) (1)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
- Isolation and Sequence of the Human Glucocorticoid Receptor Gene Promoter. Cloning of the Human Androgen Receptor cDNA (1988) (1)
- Genomic organization and expression of the mouse Brca2 gene (2002) (1)
- Genome-wide association study of germline variants and breast cancer-speci fi c mortality (2019) (1)
- Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry (2016) (1)
- Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
- Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
- Analysis of multivariate failure times in the presence of selection bias with application to breast cancer (2015) (1)
- University of Groningen Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA 1 and BRCA 2 Mutation Carriers (2017) (1)
- Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry (2022) (1)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- Antiestrogenic activity of LY156758 in adenohypophysial cells in culture (1984) (0)
- Fine-mapping identifies two additional susceptibility 9q31.2. (2015) (0)
- a novel candidate breast cancer susceptibility locus on (2017) (0)
- Authors' response: associations of obesity and circulating insulin and glucose with breast cancer risk. (2019) (0)
- Identification and characterisation of novel associations in the CASP 8 / ALS 2 CR 12 region 1 on chromosome 2 with breast cancer risk 2 3 (2014) (0)
- TITLE : Incorporating Truncating Variants in PALB 2 , CHEK 2 and ATM into the BOADICEA Breast Cancer Risk Model SHORT TITLE : Rare Variants in the BOADICEA Breast Cancer Risk Model Authorship (2016) (0)
- Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer (2022) (0)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (0)
- rs 2735383 , located at a microRNA binding site in the 3 ’ UTR of NBS 1 , is not associated with breast cancer risk (2016) (0)
- BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (0)
- Abstract 962: Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries (2019) (0)
- Erratum: Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast cancer research : BCR (2020) 22 1 (8)) (2020) (0)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
- Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects (2021) (0)
- Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (0)
- BRCA1 Gene Expression in Reproductive and Endocrine Tissues in Adult Cynomolgus Monkey (1998) (0)
- Abstract 2258: Genome-wide association studies of breast cancer prognosis (2017) (0)
- CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (0)
- Variations in Rates: why we need clinical management recommendations (2007) (0)
- Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
- Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
- Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
- Detection of a novel mutation Y468X in exon 10 of the low-density lipoprotein receptor gene causing heterozygous familial hypercholesterolemia among French Canadians (1994) (0)
- Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention (2022) (0)
- BRCA2 susceptibility gene breast cancer linked to chromosome 13. (1996) (0)
- The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index (2018) (0)
- Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? (2016) (0)
- Mutation analysis oftheBRCA1genein23 families withcases ofcancer ofthebreast, ovary, andmultiple other sites (1996) (0)
- Genome-wide association study of germline variants and breast cancer-speci fi c mortality (2019) (0)
- Mutations in the 17q-linked breast and ovariecancerprædisponeringen (1995) (0)
- OP-JNCI200131 434..442 (2021) (0)
- Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
- Structure-Function Relationships of Multiple Rat Members of (1993) (0)
- Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp 6 , des-Gly-NH 2 10 ]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience (1988) (0)
- q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
- Gene de predisposition au cancer du sein lie au chromosome 13 (1996) (0)
- In vivo mutations and polymorphisms in the 17.alpha.-coupled breast and ovarian cancer susceptibility genes (1997) (0)
- Mutations associated with the 17q ovarian and breast sensitivity gens (1995) (0)
- Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023) (0)
- ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers (2010) (0)
- Mutations in the gene for susceptibility to breast and ovarian cancer linked to 17q (1995) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- THE HETEROGENEITY OF 3β-HYDROXYSTEROID DEHYDRO GENASE (3β-HSD) DEFICIENCY - REPORT OF 4 CASES (1993) (0)
- Abstract 2783: Common functional mechanisms underlying pleiotropy at the 19p13.1 breast and ovarian cancer cusceptibility locus (2015) (0)
- Mutations of the 17q associated ovarian and breast cancer susceptibility gene (1995) (0)
- Conversion of precursor adrenal steroids into potent androgens in peripheral tissues (1989) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- Mutations of the gene related to chromosome 17q, susceptibility to cancer of breast and ovary. (1995) (0)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
- Abstract 3222: Evaluation of associations between circulating proteins and breast cancer risk using genetic variants (2018) (0)
- AD51B in Familial Breast Cancer (2016) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Rare copy number variants (CNVs) and breast cancer risk (2021) (0)
- Mutations associated with the 17q ovarian and breast cancer susceptibility gene (1995) (0)
- Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (0)
- Genetic variation in the immunosuppression pathway genes and breast cancer: a pooled analysis of 42,510 cases and 40,577 controls from the Breast (2015) (0)
- [Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis]. (1992) (0)
- Functional characterization of 84 PALB2 variants of uncertain significance (2019) (0)
- No evidence of recurent BRCA1/2 genomic rearrangement in high risk French-Canadian breast/ovarian cancer families (2003) (0)
- Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression (2016) (0)
- The Passing of Dr. Fernand Labrie (1937–2019): The legacy of excellence in science (2019) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- INHERIT BRCAs Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges (2005) (0)
- Androgens in post-menopause (1991) (0)
- Abstract 1309: Association between insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent (2017) (0)
- An Improved Polygenic Risk Score for Risk Prediction in Breast Cancer (2017) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Inhibition of Cell Cycle Kinetics and Proliferation by the Androgen 5a-Dihydrotestosterone and Antiestrogen A^,/i-Butyl-A^-methyl-ll-Undecanamide in Human Breast Cancer ZR-75-1 Cells1 (2006) (0)
- Mutations linked to chromosome 17q, susceptibility breast cancer and ovarian gene. (1995) (0)
- University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
- Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (0)
- Chromosome 13 associated Brustkrebsempfindlichkeitsgen BRCA2 (1996) (0)
- Effect of Luteinizing Hormone Releasing Hormone (LHRH) and [D-Trp, Des-Gly-NH2 (2008) (0)
- HRCA-I gene mutation is commonly identified among women with early-onset breast cancer and is particularly common in Jewish women (1996) (0)
- Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (0)
- 1.P.233 Molecular evidence of founder effect for four mutations in the low-density lipoprotein receptor gene in French Canadians with familial hypercholesterolemia (1997) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Tamoxifen and risk of contralateral breast cancer for \textitBRCA1 and \textitBRCA2 mutation carriers (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jacques Simard,?
Jacques Simard, is affiliated with the following schools: